Latest Bare-metal stent Stories
TCT- WASHINGTON, September 23, 2010 /PRNewswire/ -- InspireMD, developers of the novel MGuard(TM) coronary MicroNet stent system, will introduce MGuard Prime at its booth #2052 at the TCT Conference in Washington DC, September 23-25, 2010.
NATICK, Mass., Sept.
Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer.
NATICK, Mass., Sept.
STOCKHOLM, August 31, 2010 /PRNewswire/ -- - The Publication of 10-Year Follow-Up Test Results on the First CYPHER(R) Sirolimus-Eluting Coronary Stent Patient Reveal the Stent's Outstanding Efficacy and Safety Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a...
NATICK, Mass., Aug. 3 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of its fourth-generation SYNERGY(TM) Coronary Stent.
WALTHAM, Mass., June 29 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite the rising popularity of drug-eluting stents (DES) across Latin America, bare-metal stents (BMS) will continue to represent a significant portion of the overall coronary stent market through 2014.
VANCOUVER, June 10 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc.
NATICK, Mass., June 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the market launch and first implants of its TAXUS(Â®) Element(TM) Paclitaxel-Eluting Coronary Stent System in the European Union and other CE Mark countries.
NATICK, Mass., May 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark approval for its TAXUSÂ® Element(TM) Paclitaxel-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent (DES) technology.
- A young chicken: also used as a pet name for children.